Aligos Therapeutics Stock Market Outlook
| ALGS Stock | USD 6.99 0.00 0.00% |
Slightly above 54% of Aligos Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Aligos Therapeutics suggests that many traders are impartial. Aligos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Aligos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 46
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Aligos Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Aligos Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Aligos Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Aligos Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Aligos Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Aligos Therapeutics Advice
The Aligos recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Aligos Therapeutics. Macroaxis does not own or have any residual interests in Aligos Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Aligos Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Risky | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Aligos Therapeutics has a Mean Deviation of 4.68, Semi Deviation of 5.27, Standard Deviation of 5.91, Variance of 34.98, Downside Variance of 28.77 and Semi Variance of 27.74We provide trade advice to complement the prevailing expert consensus on Aligos Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Aligos Therapeutics is not overpriced, please confirm all Aligos Therapeutics fundamentals, including its price to book, current ratio, retained earnings, as well as the relationship between the net income and target price . Given that Aligos Therapeutics has a number of shares shorted of 293.58 K, we suggest you to validate Aligos Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Aligos Therapeutics Trading Alerts and Improvement Suggestions
| Aligos Therapeutics generated a negative expected return over the last 90 days | |
| Aligos Therapeutics has high historical volatility and very poor performance | |
| Aligos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.94 M. Net Loss for the year was (131.21 M) with loss before overhead, payroll, taxes, and interest of (65.8 M). | |
| Aligos Therapeutics currently holds about 159.34 M in cash with (80.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Roughly 61.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Aligos Therapeutics Appoints New Principal Accounting Officer - TipRanks |
Aligos Therapeutics Returns Distribution Density
The distribution of Aligos Therapeutics' historical returns is an attempt to chart the uncertainty of Aligos Therapeutics' future price movements. The chart of the probability distribution of Aligos Therapeutics daily returns describes the distribution of returns around its average expected value. We use Aligos Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Aligos Therapeutics returns is essential to provide solid investment analysis for Aligos Therapeutics.
| Mean Return | 0.17 | Value At Risk | -8.2 | Potential Upside | 11.50 | Standard Deviation | 5.91 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Aligos Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Aligos Stock Institutional Investors
The Aligos Therapeutics' institutional investors refer to entities that pool money to purchase Aligos Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Geode Capital Management, Llc | 2025-06-30 | 34 K | Lpl Financial Corp | 2025-06-30 | 30.1 K | Charles Schwab Investment Management Inc | 2025-06-30 | 25.4 K | Squarepoint Ops Llc | 2025-06-30 | 18.6 K | Citadel Advisors Llc | 2025-06-30 | 15.2 K | Xtx Topco Ltd | 2025-06-30 | 13.8 K | Wells Fargo & Co | 2025-06-30 | 13.8 K | Blackrock Inc | 2025-06-30 | 13 K | Millennium Management Llc | 2025-06-30 | 12.3 K | Woodline Partners Lp | 2025-06-30 | 518.3 K | Deep Track Capital, Lp | 2025-06-30 | 444.1 K |
Aligos Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | 3.9M | (25.4M) | 45.0M | (18.3M) | (21.0M) | (20.0M) | |
| Change In Cash | (34.0M) | (105.5M) | 54.3M | (98.7M) | (88.8M) | (84.4M) | |
| Net Borrowings | (79K) | (61K) | (96K) | (83K) | (74.7K) | (71.0K) | |
| Free Cash Flow | (116.6M) | (80.3M) | (79.0M) | (80.9M) | (72.8M) | (76.4M) | |
| Depreciation | 3.8M | 3.7M | 3.1M | 2.6M | 3.0M | 3.2M | |
| Other Non Cash Items | 86K | (159K) | 2.5M | 44.3M | 51.0M | 53.6M | |
| Capital Expenditures | 892K | 943K | 19K | 130K | 117K | 111.2K | |
| Net Income | (128.3M) | (96.0M) | (87.7M) | (131.2M) | (118.1M) | (124.0M) | |
| End Period Cash Flow | 187.0M | 81.5M | 135.8M | 37.1M | 42.7M | 40.5M | |
| Change To Netincome | (473K) | 14.9M | 13.5M | 14.7M | 16.9M | 9.7M |
Aligos Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Aligos Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Aligos Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Aligos stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 0.67 | |
σ | Overall volatility | 5.63 | |
Ir | Information ratio | 0.02 |
Aligos Therapeutics Volatility Alert
Aligos Therapeutics exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Aligos Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Aligos Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Aligos Therapeutics Fundamentals Vs Peers
Comparing Aligos Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Aligos Therapeutics' direct or indirect competition across all of the common fundamentals between Aligos Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Aligos Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Aligos Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Aligos Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Aligos Therapeutics to competition |
| Fundamentals | Aligos Therapeutics | Peer Average |
| Return On Equity | -1.42 | -0.31 |
| Return On Asset | -0.55 | -0.14 |
| Operating Margin | (38.27) % | (5.51) % |
| Current Valuation | (50.51 M) | 16.62 B |
| Shares Outstanding | 5.35 M | 571.82 M |
| Shares Owned By Insiders | 10.36 % | 10.09 % |
| Shares Owned By Institutions | 60.74 % | 39.21 % |
| Number Of Shares Shorted | 293.58 K | 4.71 M |
| Price To Book | 0.59 X | 9.51 X |
| Price To Sales | 16.07 X | 11.42 X |
| Revenue | 3.94 M | 9.43 B |
| Gross Profit | (65.8 M) | 27.38 B |
| EBITDA | (86.53 M) | 3.9 B |
| Net Income | (131.21 M) | 570.98 M |
| Cash And Equivalents | 159.34 M | 2.7 B |
| Cash Per Share | 3.72 X | 5.01 X |
| Total Debt | 8.38 M | 5.32 B |
| Debt To Equity | 0.1 % | 48.70 % |
| Current Ratio | 5.30 X | 2.16 X |
| Book Value Per Share | 11.67 X | 1.93 K |
| Cash Flow From Operations | (80.74 M) | 971.22 M |
| Short Ratio | 3.77 X | 4.00 X |
| Earnings Per Share | (13.54) X | 3.12 X |
| Target Price | 68.2 | |
| Number Of Employees | 70 | 18.84 K |
| Beta | 2.66 | -0.15 |
| Market Capitalization | 42.52 M | 19.03 B |
| Total Asset | 70.09 M | 29.47 B |
| Retained Earnings | (618.01 M) | 9.33 B |
| Working Capital | 40.4 M | 1.48 B |
| Net Asset | 70.09 M |
Note: Acquisition by Calhoun Lesley Ann of 40185 shares of Aligos Therapeutics at 8.68 subject to Rule 16b-3 [view details]
Aligos Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Aligos . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.1 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 7.31 | |||
| Day Typical Price | 7.2 | |||
| Market Facilitation Index | 0.8 | |||
| Price Action Indicator | (0.32) |
About Aligos Therapeutics Buy or Sell Advice
When is the right time to buy or sell Aligos Therapeutics? Buying financial instruments such as Aligos Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Aligos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.